The Skinny on the GLP-1 and GIP/GLP-1 Market

Leveraging Sermo's Brand Pulse and Talking Medicines’ Drug-GPT™, we set out to better understand current challenges as well as perceptions, attitudes, and usage around GLP-1 and GIP/GIP-1 medications among patients and physicians.

Download our exclusive report to:

• Gain insight into how GLP-1 and GIP/GLP-1 drugs have revolutionized the type 2 diabetes space
• Explore how physicians and patients alike are talking, thinking, and reacting to GLP-1 and GIP/GLP-1 medications
• Deep dive into learnings about specific medications like semaglutide and tirzepatide both from the physician and patient perspective